AsiaOne

AsiaOne

AsiaOne

AsiaOne | 2021-07-20 12:15

LOS ANGELES, July 20, 2021 (GLOBE NEWSWIRE) -- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, today announced that it has completed a financing round of US$6.2 million led by AXA IM, through AXA IM Alts, a global leader in alternative investments with c. €162 billion of assets under management. Eyenuk's existing investors also participated in the round. Eyenuk will use the proceeds to immediately accelerate commercialization of the EyeArt AI System, which received FDA clearance in 2020 and is being reimbursed by Medicare and other payors. AXA IM Alts' investment in Eyenuk is advised by Dr. Zina Affas Besse, Managing Partner at Global Health Investment Advisors (GHIA), a pioneer in impact investing in life science companies. "We are very impressed with all that the Eyenuk team h…


Become a DPEX Community member to access
data protection resouces and discussions on pertinent topics now.

Access online / in-person courses and view past training records

Join lively discussions on pertinent data protection topics

Gain access to data protection research and video resources

Receive value-added data protection updates from the region